StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) News 'Somewhat Astonishing', Shares Could Trade Back Toward Low-$300s - RBC
October 22, 2019 7:32 AM
RBC Capital analyst Brian Abrahams weighed in on news Biogen (NASDAQ: BIIB) will pursue regulatory ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Trader Talk
Next Articles
Biogen (BIIB) PT Raised to $305 at Canaccord Genuity
October 23, 2019 5:14 AM
Biogen (BIIB) PT Raised to $297 at BMO Capital
October 23, 2019 4:44 AM
Biogen (BIIB) PT Raised to $310 at Jefferies
October 22, 2019 1:45 PM
Biogen (BIIB) Tops Q3 EPS by 90c
October 22, 2019 6:53 AM
Biogen (BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimer’s Disease
October 22, 2019 6:41 AM
Biogen (BIIB) Says it Plans Regulatory Filing for Aducanumab in Alzheimer's Disease After Consulting with FDA
October 22, 2019 6:33 AM
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
October 22, 2019 6:31 AM
